百日咳(Pertussis)の治療薬パイプライン動向（2015年上半期版）...市場調査レポートについてご紹介

Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Pertussis Overview 10
Therapeutics Development 11
Pipeline Products for Pertussis – Overview 11
Pipeline Products for Pertussis – Comparative Analysis 12
Pertussis – Therapeutics under Development by Companies 13
Pertussis – Therapeutics under Investigation by Universities/Institutes 16
Pertussis – Pipeline Products Glance 17
Late Stage Products 17
Clinical Stage Products 18
Early Stage Products 19
Unknown Stage Products 20
Pertussis – Products under Development by Companies 21
Pertussis – Products under Investigation by Universities/Institutes 23
Pertussis – Companies Involved in Therapeutics Development 24
Beijing Minhai Biotechnology Co., Ltd 24
Beijing Tiantan Biological Products Co., Ltd. 25
Bharat Biotech International Limited 26
Biological E. Limited 27
Daiichi Sankyo Company, Limited 28
DBV Technologies S.A. 29
Green Cross Corporation 30
Indian Immunologicals Limited 31
LG Life Sciences, Ltd. 32
NanoBio Corporation 33
Novartis AG 34
Panacea Biotec Limited 35
Sanofi 36
Sanofi Pasteur SA 37
Serum Institute of India Limited 38
Sinovac Biotech Ltd. 39
Synthetic Biologics, Inc. 40
Takeda Pharmaceutical Company Limited 41
Zydus Cadila Healthcare Limited 42
Pertussis – Therapeutics Assessment 43
Assessment by Monotherapy Products 43
Assessment by Combination Products 44
Assessment by Target 45
Assessment by Route of Administration 47
Assessment by Molecule Type 49
Drug Profiles 51
(diphtheria + tetanus + pertussis (acelluar) + poliovirus (types 1, 2 ,3)) vaccine – Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
(diphtheria + tetanus + pertussis (acellular) + hepatitis B + poliomyelitis + haemophilus influenza [serogroup B]) vaccine – Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
diphtheria + pertussis + tetanus + hepatitis [serotype B] + haemophilus influenza [serotype B] vaccine – Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
diphtheria + pertussis + tetanus vaccine – Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
diphtheria + pertussis + tetanus vaccine – Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
diphtheria + tetanus + pertussis (acellular) vaccine – Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
diphtheria + tetanus + pertussis (acellular) vaccine – Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
diphtheria + tetanus + pertussis (whole cell) + haemophilus influenzae [type B] + polio (pentavalent) vaccine – Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
diphtheria + tetanus + pertussis (whole cell) + hepatitis B + haemophilus influenzae [type B] + polio (hexavalent) vaccine – Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
diphtheria + tetanus + pertussis (whole-cell) + haemophilus influenzae [serotype B] vaccine – Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
diphtheria + tetanus + pertussis (whole-cell) + hepatitis B + haemophilus influenzae [serotype B] (pentavalent) vaccine – Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
diphtheria + tetanus + pertussis (whole-cell) + hepatitis B + haemophilus influenzae [serotype B] vaccine – Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
diphtheria + tetanus + pertussis (whole-cell) + poliomyelitis + haemophilus influenzae [serotype B] + hepatitis B + meningococcal [serotype C] (7-valent) vaccine – Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
diphtheria + tetanus+ pertussis (wholecell) + hepatitis [Type B] + haemophilus influenzae [type B] (pentavalent) vaccine – Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
diphtheria + tetanus+ pertussis (wholecell) + hepatitis [Type B] + poliomyelitis + haemophilus influenzae [type B] (hexavalent) vaccine – Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
diphtheria + tetanus+ pertussis vaccine – Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
diptheria + tetanus + pertussis (whole-cell) vaccine – Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
DTaP Vaccine – Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
GC-3111A – Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
pertussis (acellular) vaccine – Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
pertussis (acellular) vaccine – Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
pertussis (whole-cell) vaccine – Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
pertussis + hepatitis B vaccine – Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
pertussis vaccine – Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
pertussis vaccine – Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
pertussis vaccine – Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
pertussis vaccine – Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
pertussis vaccine – Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
Recombinant BCG – Pertussis Vaccine – Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
SYN-005 – Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
TAK-361S – Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
tetanus + diphtheria + pertussis (acellular) vaccine – Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
VN-0103 – Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
Pertussis – Recent Pipeline Updates 86
Pertussis – Dormant Projects 88
Pertussis – Product Development Milestones 90
Featured News & Press Releases 90
Nov 14, 2014: Biological E To Supply Pentavalent Vaccine For Telangana State Immunization Program 90
Oct 20, 2014: US FDA Accepts for Review a Biologics License Application for Merck and Sanofi Pasteur’s Investigational Pediatric Hexavalent Vaccine 90
Sep 12, 2014: Synthetic Biologics Receives Orphan Drug Designation for SYN-005 Treatment for Whooping Cough (Pertussis) 91
Aug 19, 2014: Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 92
Apr 23, 2014: Synthetic Biologics’ Reports Preclinical Data to Support Clinical Development of Novel Pertussis Therapeutic 92
Apr 01, 2014: Sanofi Pasteur Announces FDA Has Expanded Age Indication of Adacel® Tdap Vaccine to Include Persons 10 Years of Age 93
Apr 22, 2013: Sanofi Obtains European Approval For Six-in-One Pediatric Vaccine Hexyon/Hexacima 94
Feb 22, 2013: Sanofi Pasteur Announces EMA’s CHMP Recommends Approval Of Hexyon/Hexacima Six-In-One Pediatric Vaccine 95
Dec 20, 2012: Synthetic Biologics And Intrexon Initiate Development Of Monoclonal Antibodies For Whooping Cough 96
Oct 19, 2012: Sanofi Pasteur To Commercialize New 6-in-1 Paediatric Vaccine In European Markets 96
Appendix 98
Methodology 98
Coverage 98
Secondary Research 98
Primary Research 98
Expert Panel Validation 98
Contact Us 99
Disclaimer 99